Efficacy and safety of prolonged release budesonide granules in mesalazine‐refractory ulcerative colitis: A multi‐centre Phase IIa study (TOPICAL‐1)
Klaus Fellermann(Apple (Israel)), Roland Greinwald(Dr Falk Pharma (Germany)), I Rácz(Petz Aladár Megyei Oktató Kórház), Jeļena Derova(Latvian Maritime Academy), Sarah Wehrum(Dr Falk Pharma (Germany)), Laimas Virginijus Jonaitis(Lithuanian University of Health Sciences), Tanju Nacak(Dr Falk Pharma (Germany)), Ingolf Schiefke(University Hospital Leipzig)
Cited by 5
Related Papers
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
|Endoscopy|2015|823
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566